Neurocrine Biosciences
NBIX
#1659
Rank
NZ$22.45 B
Marketcap
NZ$223.28
Share price
-1.25%
Change (1 day)
33.07%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): NZ$1.08 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.86 Billion. , an increase over its 2024 earnings that were of NZ$1.03 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 NZ$1.08 B3.9%
2024 NZ$1.03 B96.41%
2023 NZ$0.52 B41.13%
2022 NZ$0.37 B73.74%
2021 NZ$0.21 B-8.82%
2020 NZ$0.23 B77.78%
2019 NZ$0.13 B49.83%
2018 NZ$88.86 M-142.57%
2017 -NZ$0.21 Billion-14.73%
2016 -NZ$0.25 Billion53.15%
2015 -NZ$0.16 Billion46.25%
2014 -NZ$0.11 Billion29.66%
2013 -NZ$84.3 Million-3530.8%
2012 NZ$2.45 M-95.73%
2011 NZ$57.55 M
2009 -NZ$80.92 Million-45.38%
2008 -NZ$0.15 Billion-58.87%
2007 -NZ$0.37 Billion87.3%
2006 -NZ$0.2 Billion351.97%
2005 -NZ$42.55 Million-52.09%
2004 -NZ$88.81 Million-10.98%
2003 -NZ$99.75 Million
2001 -NZ$74.46 Million
1999 -NZ$33.58 Million108.32%
1998 -NZ$16.12 Million
1996 NZ$4.92 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$17.29 B 1,501.26%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$11.19 B 936.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$43.66 B 3,942.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$0.14 B-86.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$70.87 Million-106.56%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$85.77 M-92.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-NZ$8.14 Million-100.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.76 B 156.38%๐Ÿ‡ฌ๐Ÿ‡ง UK